[{"id":"a24dd70d-457e-4bf3-b1b4-2106aa67a692","acronym":"","url":"https://clinicaltrials.gov/study/NCT07064018","created_at":"2025-07-19T14:18:32.626Z","updated_at":"2025-07-19T14:18:32.626Z","phase":"Phase 1/2","brief_title":"Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies","source_id_and_acronym":"NCT07064018","lead_sponsor":"University of California, Irvine","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Neulasta (pegfilgrastim) • Neupogen (filgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 67","initiation":"Initiation: 04/30/2025","start_date":" 04/30/2025","primary_txt":" Primary completion: 12/31/2029","primary_completion_date":" 12/31/2029","study_txt":" Completion: 12/31/2031","study_completion_date":" 12/31/2031","last_update_posted":"2025-07-14"},{"id":"4bf912ed-2f96-4d90-aef7-e45022410420","acronym":"","url":"https://clinicaltrials.gov/study/NCT00186888","created_at":"2025-07-19T13:43:51.175Z","updated_at":"2025-07-19T13:43:51.175Z","phase":"Phase 3","brief_title":"Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma","source_id_and_acronym":"NCT00186888","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" ABCG2 • CYP3A4","pipe":"","alterations":" ","tags":["ABCG2 • CYP3A4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • Neupogen (filgrastim)"],"overall_status":"Completed","enrollment":" Enrollment 107","initiation":"Initiation: 04/07/2005","start_date":" 04/07/2005","primary_txt":" Primary completion: 11/01/2013","primary_completion_date":" 11/01/2013","study_txt":" Completion: 11/12/2024","study_completion_date":" 11/12/2024","last_update_posted":"2025-04-15"},{"id":"23898e8b-63ed-4913-ab7c-2d5d7699806b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02339571","created_at":"2021-01-18T11:07:01.092Z","updated_at":"2025-02-25T12:26:15.021Z","phase":"Phase 2/3","brief_title":"A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma","source_id_and_acronym":"NCT02339571","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF wild-type","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • Leukine (sargramostim)"],"overall_status":"Recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 11/23/2015","start_date":" 11/23/2015","primary_txt":" Primary completion: 06/30/2033","primary_completion_date":" 06/30/2033","study_txt":" Completion: 06/30/2033","study_completion_date":" 06/30/2033","last_update_posted":"2025-02-24"},{"id":"44c07294-8489-4b3a-b2ed-b2c7e11ad982","acronym":"NCI#10057","url":"https://clinicaltrials.gov/study/NCT02978625","created_at":"2021-01-18T14:39:10.615Z","updated_at":"2025-02-25T13:48:20.165Z","phase":"Phase 2","brief_title":"Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers","source_id_and_acronym":"NCT02978625 - NCI#10057","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • ALK • NECTIN1","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["PD-L1 • ALK • NECTIN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Imlygic (talimogene laherparepvec) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 09/27/2017","start_date":" 09/27/2017","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-02-21"},{"id":"b813594c-e262-462c-9ebd-af975b8871b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04375631","created_at":"2021-01-18T21:08:17.296Z","updated_at":"2025-02-25T13:53:16.560Z","phase":"Phase 1","brief_title":"CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia","source_id_and_acronym":"NCT04375631","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • cyclophosphamide • idarubicin hydrochloride • mitoxantrone • cladribine • fludarabine IV • cyclosporin A microemulsion • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 12/03/2020","start_date":" 12/03/2020","primary_txt":" Primary completion: 02/28/2027","primary_completion_date":" 02/28/2027","study_txt":" Completion: 03/17/2027","study_completion_date":" 03/17/2027","last_update_posted":"2025-02-20"},{"id":"99c4032a-3714-4351-a6af-2208fcba233e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04684368","created_at":"2021-01-19T20:47:18.675Z","updated_at":"2025-02-25T15:11:50.245Z","phase":"Phase 2","brief_title":"A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT","source_id_and_acronym":"NCT04684368","lead_sponsor":"Children's Oncology Group","biomarkers":" NF1","pipe":" | ","alterations":" AFP elevation","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AFP elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • cyclophosphamide • ifosfamide • etoposide IV • mesna • thiotepa • Neulasta (pegfilgrastim) • Fulphila (pegfilgrastim-jmdb) • Neupogen (filgrastim) • Udenyca (pegfilgrastim-cbqv) • Ziextenzo (pegfilgrastim-bmez) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 07/13/2021","start_date":" 07/13/2021","primary_txt":" Primary completion: 12/21/2029","primary_completion_date":" 12/21/2029","study_txt":" Completion: 12/21/2029","study_completion_date":" 12/21/2029","last_update_posted":"2025-02-13"},{"id":"6a48c7f0-faef-41c8-a9fa-31b1481860b7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02779855","created_at":"2021-01-18T13:37:46.654Z","updated_at":"2025-02-25T15:25:27.556Z","phase":"Phase 1/2","brief_title":"Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer","source_id_and_acronym":"NCT02779855","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 amplification","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Imlygic (talimogene laherparepvec)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 05/02/2017","start_date":" 05/02/2017","primary_txt":" Primary completion: 09/20/2020","primary_completion_date":" 09/20/2020","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2025-02-10"},{"id":"3a5c5d6a-237c-4943-9f23-41234e0aa377","acronym":"","url":"https://clinicaltrials.gov/study/NCT03755804","created_at":"2021-01-18T18:27:48.805Z","updated_at":"2025-02-25T16:37:17.115Z","phase":"Phase 2","brief_title":"Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17","source_id_and_acronym":"NCT03755804","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" TNFRSF8","pipe":"","alterations":" ","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Adcetris (brentuximab vedotin) • vincristine • prednisone • dacarbazine • bendamustine • bleomycin • vinblastine • Neupogen (filgrastim) • cyclophosphamide intravenous • prednisolone"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 12/12/2018","start_date":" 12/12/2018","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-07"},{"id":"2da9c54d-f433-496f-be98-f97e66600d34","acronym":"MCC-20575","url":"https://clinicaltrials.gov/study/NCT04610671","created_at":"2021-01-19T20:32:23.268Z","updated_at":"2025-02-25T16:38:06.492Z","phase":"Phase 1","brief_title":"Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC","source_id_and_acronym":"NCT04610671 - MCC-20575","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" CD8","pipe":" | ","alterations":" PD-L1 expression","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • cretostimogene grenadenorepvec (CG0070)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 10/26/2020","start_date":" 10/26/2020","primary_txt":" Primary completion: 01/18/2025","primary_completion_date":" 01/18/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-06"},{"id":"ba0b6173-d6ba-4d9f-b7a6-14e36795d0f2","acronym":"","url":"https://clinicaltrials.gov/study/NCT02337985","created_at":"2021-01-18T11:06:20.660Z","updated_at":"2025-02-25T16:36:30.633Z","phase":"Phase 1","brief_title":"Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT02337985","lead_sponsor":"City of Hope Medical Center","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • etoposide oral • vincristine • prednisone • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 11/20/2015","start_date":" 11/20/2015","primary_txt":" Primary completion: 10/02/2025","primary_completion_date":" 10/02/2025","study_txt":" Completion: 10/02/2025","study_completion_date":" 10/02/2025","last_update_posted":"2025-02-06"},{"id":"71628f3d-27a7-487c-a8bd-86587a5fa22b","acronym":"","url":"https://clinicaltrials.gov/study/NCT00026312","created_at":"2023-11-21T19:15:23.482Z","updated_at":"2025-02-25T16:50:44.915Z","phase":"Phase 3","brief_title":"Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma","source_id_and_acronym":"NCT00026312","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MYCN • NCR3LG1","pipe":"","alterations":" ","tags":["MYCN • NCR3LG1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Proleukin (aldesleukin) • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • Leukine (sargramostim)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1449","initiation":"Initiation: 10/18/2001","start_date":" 10/18/2001","primary_txt":" Primary completion: 01/12/2012","primary_completion_date":" 01/12/2012","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2025-02-04"},{"id":"de3b1a71-0b74-42e6-87b8-569689ad09da","acronym":"","url":"https://clinicaltrials.gov/study/NCT03153410","created_at":"2025-02-25T16:06:15.779Z","updated_at":"2025-02-25T16:06:15.779Z","phase":"Phase 1","brief_title":"Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas","source_id_and_acronym":"NCT03153410","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) • LY3022855"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 09/27/2018","start_date":" 09/27/2018","primary_txt":" Primary completion: 03/09/2022","primary_completion_date":" 03/09/2022","study_txt":" Completion: 08/29/2023","study_completion_date":" 08/29/2023","last_update_posted":"2025-01-09"},{"id":"b2c9ef7d-2fb3-45a4-a86b-257c668139cf","acronym":"","url":"https://clinicaltrials.gov/study/NCT03767582","created_at":"2021-02-23T17:53:27.774Z","updated_at":"2025-02-25T14:27:51.862Z","phase":"Phase 1/2","brief_title":"Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.","source_id_and_acronym":"NCT03767582","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" TNFRSF9","pipe":"","alterations":" ","tags":["TNFRSF9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • BMS-813160 • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells)"],"overall_status":"Completed","enrollment":" Enrollment 46","initiation":"Initiation: 12/12/2019","start_date":" 12/12/2019","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-12-10"},{"id":"4b76673c-cd8f-4b3e-aab1-a119e574fcaa","acronym":"MASTERKEY318","url":"https://clinicaltrials.gov/study/NCT02509507","created_at":"2021-01-18T12:07:01.792Z","updated_at":"2025-02-25T16:14:58.621Z","phase":"Phase 1/2","brief_title":"Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611","source_id_and_acronym":"NCT02509507 - MASTERKEY318","lead_sponsor":"Amgen","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HR positive • ER negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Imlygic (talimogene laherparepvec)"],"overall_status":"Completed","enrollment":" Enrollment 127","initiation":"Initiation: 02/05/2016","start_date":" 02/05/2016","primary_txt":" Primary completion: 02/14/2022","primary_completion_date":" 02/14/2022","study_txt":" Completion: 07/11/2023","study_completion_date":" 07/11/2023","last_update_posted":"2024-08-06"},{"id":"ea8aa5eb-747e-43c1-9888-86c7239699c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT00547196","created_at":"2021-01-18T01:59:32.370Z","updated_at":"2024-07-02T16:34:25.798Z","phase":"","brief_title":"AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies \u0026 Disorders","source_id_and_acronym":"NCT00547196","lead_sponsor":"City of Hope Medical Center","biomarkers":" KMT2A • HLA-DRB1 • HLA-B","pipe":"","alterations":" ","tags":["KMT2A • HLA-DRB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • melphalan • fludarabine IV • busulfan • cyclosporine • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 08/16/2005","start_date":" 08/16/2005","primary_txt":" Primary completion: 11/11/2009","primary_completion_date":" 11/11/2009","study_txt":" Completion: 05/28/2024","study_completion_date":" 05/28/2024","last_update_posted":"2024-06-14"},{"id":"897414a3-bc36-4d90-b0c6-902256e6b2d3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02334865","created_at":"2021-02-24T21:53:04.763Z","updated_at":"2025-02-25T14:35:10.773Z","phase":"Phase 1","brief_title":"SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy","source_id_and_acronym":"NCT02334865","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02 • HLA-A*24","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A*24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • SurVaxM (SVN53-67/M57-KLH peptide vaccine) • Leukine (sargramostim)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 04/13/2017","start_date":" 04/13/2017","primary_txt":" Primary completion: 09/16/2022","primary_completion_date":" 09/16/2022","study_txt":" Completion: 05/19/2026","study_completion_date":" 05/19/2026","last_update_posted":"2024-06-04"},{"id":"bda81f7a-e7db-4896-93fc-dd002a685704","acronym":"","url":"https://clinicaltrials.gov/study/NCT05101356","created_at":"2023-10-12T19:12:04.905Z","updated_at":"2024-07-02T16:35:02.238Z","phase":"Phase 1/2","brief_title":"A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma","source_id_and_acronym":"NCT05101356","lead_sponsor":"Tianhong Li","biomarkers":" EGFR • BRAF • ALK • ROS1 • NTRK","pipe":" | ","alterations":" BRAF mutation • MET mutation","tags":["EGFR • BRAF • ALK • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • MET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Labvax 3(22)-23 • Leukine (sargramostim)"],"overall_status":"Recruiting","enrollment":" Enrollment 77","initiation":"Initiation: 10/13/2021","start_date":" 10/13/2021","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2030","study_completion_date":" 01/01/2030","last_update_posted":"2024-05-21"},{"id":"6c2e39ce-123b-43b3-a0b9-013302070a36","acronym":"","url":"https://clinicaltrials.gov/study/NCT01740297","created_at":"2021-01-17T17:36:18.459Z","updated_at":"2024-07-02T16:35:03.840Z","phase":"Phase 1/2","brief_title":"Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma","source_id_and_acronym":"NCT01740297","lead_sponsor":"Amgen","biomarkers":" BRAF • PD-1 • CTLA4","pipe":" | ","alterations":" BRAF mutation • BRAF wild-type","tags":["BRAF • PD-1 • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • Imlygic (talimogene laherparepvec)"],"overall_status":"Completed","enrollment":" Enrollment 217","initiation":"Initiation: 02/07/2013","start_date":" 02/07/2013","primary_txt":" Primary completion: 08/23/2016","primary_completion_date":" 08/23/2016","study_txt":" Completion: 03/09/2021","study_completion_date":" 03/09/2021","last_update_posted":"2024-05-14"},{"id":"b2fc6887-a084-4aa0-93a1-942ca0ac28d0","acronym":"MUKnineb","url":"https://clinicaltrials.gov/study/NCT03188172","created_at":"2021-01-18T15:43:10.893Z","updated_at":"2025-02-25T14:26:26.313Z","phase":"Phase 2","brief_title":"MUK Nine b: OPTIMUM Treatment Protocol","source_id_and_acronym":"NCT03188172 - MUKnineb","lead_sponsor":"University of Leeds","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • bortezomib • cyclophosphamide • Darzalex (daratumumab) • dexamethasone • melphalan • Neupogen (filgrastim)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 09/28/2017","start_date":" 09/28/2017","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2024-05-14"},{"id":"70a85930-45f1-44ec-a12c-59b3fc3ab7e5","acronym":"BMT CTN 1401","url":"https://clinicaltrials.gov/study/NCT02728102","created_at":"2021-01-18T13:21:14.849Z","updated_at":"2024-07-02T16:35:05.528Z","phase":"Phase 2","brief_title":"Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)","source_id_and_acronym":"NCT02728102 - BMT CTN 1401","lead_sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • melphalan • Leukine (sargramostim)"],"overall_status":"Completed","enrollment":" Enrollment 203","initiation":"Initiation: 07/01/2016","start_date":" 07/01/2016","primary_txt":" Primary completion: 06/30/2020","primary_completion_date":" 06/30/2020","study_txt":" Completion: 12/09/2022","study_completion_date":" 12/09/2022","last_update_posted":"2024-05-07"},{"id":"2283fe0f-f8ab-4a43-8da4-f3e6948ef310","acronym":"","url":"https://clinicaltrials.gov/study/NCT03842943","created_at":"2021-01-18T18:58:12.448Z","updated_at":"2024-07-02T16:35:06.412Z","phase":"Phase 2","brief_title":"Neoadjuvant Combination Immunotherapy for Stage III Melanoma","source_id_and_acronym":"NCT03842943","lead_sponsor":"University of Louisville","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Imlygic (talimogene laherparepvec)"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 07/03/2019","start_date":" 07/03/2019","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2024-05-02"},{"id":"1fd5f0e8-8e90-49e8-8707-ca043ad0939b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02169609","created_at":"2021-01-18T10:06:37.044Z","updated_at":"2024-07-02T16:35:08.309Z","phase":"Phase 2","brief_title":"Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma","source_id_and_acronym":"NCT02169609","lead_sponsor":"Fundació Sant Joan de Déu","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Unituxin (dinutuximab) • Leukine (sargramostim)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 11/26/2014","start_date":" 11/26/2014","primary_txt":" Primary completion: 12/26/2016","primary_completion_date":" 12/26/2016","study_txt":" Completion: 12/31/2018","study_completion_date":" 12/31/2018","last_update_posted":"2024-04-22"},{"id":"0130cadc-804e-436f-a2b2-19a2f539a6a6","acronym":"NCI-2018-03732","url":"https://clinicaltrials.gov/study/NCT03786783","created_at":"2021-01-18T18:43:54.532Z","updated_at":"2024-07-02T16:35:09.101Z","phase":"Phase 2","brief_title":"Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma","source_id_and_acronym":"NCT03786783 - NCI-2018-03732","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MYCN • IL6 • CXCL9","pipe":" | ","alterations":" MYCN amplification • IL6 expression","tags":["MYCN • IL6 • CXCL9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification • IL6 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • Leukine (sargramostim) • cyclophosphamide intravenous • dexrazoxane"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 03/04/2019","start_date":" 03/04/2019","primary_txt":" Primary completion: 12/31/2021","primary_completion_date":" 12/31/2021","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2024-04-17"},{"id":"326aa538-e6f6-455d-934e-8fdebc455f69","acronym":"","url":"https://clinicaltrials.gov/study/NCT05799612","created_at":"2023-04-05T14:03:29.792Z","updated_at":"2024-07-02T16:35:12.858Z","phase":"Phase 1","brief_title":"Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma","source_id_and_acronym":"NCT05799612","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Neupogen (filgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 03/22/2024","start_date":" 03/22/2024","primary_txt":" Primary completion: 12/31/2029","primary_completion_date":" 12/31/2029","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2024-03-26"}]